Short answer
Adicet Bio Inc (ACET) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced for quarter ended June 30, 2026.
Adicet Bio Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Exhibit 99.1 contains the accompanying earnings press release for investor review
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $21.4M, or $1.99 per share, versus $31.2M, or $5.48, in Q2 2025
- Cash, equivalents and short-term investments $118.2M, funding operations into the second half of 2027
- Prula-cel data from 22 LN/SLE patients expected in 3Q 2026, including 13 with at least 12 months follow-up
- FDA discussions support potential pivotal LN trial planning, with startup activities targeted for 2H 2026
- ADI-212 regulatory filing targeted for 3Q 2026 and Phase 1 enrollment for 4Q 2026, pending clearance
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Adicet Bio Inc 8-K filings
Get the next ACET 8-K as it lands
Follow ACET for push alerts, or ask the research agent what this filing means.